Humacyte regains ex-US Symvess distribution rights, targets international expansion

• Humacyte realigned ex-U.S. rights to Symvess under an amended distribution agreement with Fresenius Medical Care.
• Revised terms give Humacyte exclusive rights to distribute Symvess outside U.S.
• Fresenius Medical Care will receive low-single-digit royalties on Humacyte net sales of Symvess outside U.S.
• Existing terms for U.S. distribution of Symvess remain unchanged.
• Change positions Humacyte to pursue international expansion initiatives previously outlined for Saudi Arabia, Israel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-048164), on April 24, 2026, and is solely responsible for the information contained therein.